ArticleArchives of medical science : AMS2022
The association of platelet counts with development and treatment for retinopathy of prematurity - is thrombocytopenia a risk factor?
Article in Archives of medical science : AMS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.
- Biomarkers in retinopathy of prematurity: a systematic review and meta-analysis.Frontiers in pediatrics · 2024Pooled it
- Optimizing platelet transfusion thresholds in preterm infants: a systematic review and narrative synthesis of impacts on survival and neurodevelopment.Blood transfusion = Trasfusione del sanguePooled it
- Degree of thrombocytopenia and severity of retinopathy of prematurity.Journal of perinatology : official journal of the California Perinatal Association · 2026Article
- Risk factors for severe retinopathy of prematurity: A retrospective case-control study.Experimental and therapeutic medicine · 2026Article
- From Blood Count Parameters to ROP Risk: Early Hematological Predictors in Preterm Infants.Medicina (Kaunas, Lithuania) · 2025Article
- Progress in the study of association between hematological indicators and retinopathy of prematurity (Review).Biomedical reports · 2024Review
- Platelet Counts and Risk of Severe Retinopathy of Prematurity: A Bayesian Model-Averaged Meta-Analysis.Children (Basel, Switzerland) · 2023Review
- The Role of Thrombocyte Parameters in Retinopathy of Prematurity Development.International journal of clinical practice · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Thrombocytes may regulate the activity of vascular endothelial growth factor (VEGF), limiting neovascularization in retinopathy of prematurity (ROP). The aim of this study was to examine the role of platelet counts, thrombocytopenia, and infections in the pathogenesis of ROP. Material and methods: The study included 163 preterm infants diagnosed with ROP, comparing 76 patients who required treatment with 87 patients in whom ROP resolved spontaneously (control group). Further analysis concerned 52 patients in whom a first line treatment was sufficient to stop ROP progression, and 24 patients who required re-treatment. Results: A statistically significant difference was found in the occurrence of thrombocytopenia ( Conclusions: The results of the study confirm the association between ROP development and its severity with thrombocytopenia. While there were no differences in the occurrence of thrombocytopenia right after the birth, its episode before the diagnosis of ROP seems to be significant for ROP development. The deficiency of platelets prior to a treatment intervention may be associated with necessity of re-treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.